Is Innova Captab overvalued or undervalued?

Sep 16 2025 08:05 AM IST
share
Share Via
As of September 15, 2025, Innova Captab's valuation is considered fair with a PE ratio of 37.74, higher than Sun Pharma's 33.52 but lower than Divi's Lab's 69.55, and it has underperformed the Sensex by 22.46% year-to-date.
As of 15 September 2025, the valuation grade for Innova Captab has moved from attractive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a PE ratio of 37.74, an EV to EBITDA of 26.36, and a PEG ratio of 1.05.

In comparison to its peers, Innova Captab's PE ratio is higher than Sun Pharma's 33.52, but lower than Divi's Lab's significantly high 69.55. Additionally, while Cipla shows a more attractive PE of 23.18, Innova Captab's valuation remains in line with the industry average. Notably, the company's stock has underperformed the Sensex year-to-date, with a decline of 22.46% compared to the Sensex's gain of 4.67%.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News